Share This Page
Litigation Details for Cephalon, Inc. v. Nang Kuang Pharmaceutical Co LTD (D. Del. 2014)
✉ Email this page to a colleague
Cephalon, Inc. v. Nang Kuang Pharmaceutical Co LTD (D. Del. 2014)
| Docket | 1:14-cv-01117 | Date Filed | 2014-09-02 |
| Court | District Court, D. Delaware | Date Terminated | 2014-10-03 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 8,436,190; 8,445,524; 8,609,863; 8,791,270 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Cephalon, Inc. v. Nang Kuang Pharmaceutical Co LTD
Details for Cephalon, Inc. v. Nang Kuang Pharmaceutical Co LTD (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-09-02 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Cephalon v. Nang Kuang Pharmaceutical (1:14-cv-01117): Litigation Summary, Patent Scope, and Generic Entry Risk
What happened in Cephalon, Inc. v. Nang Kuang Pharmaceutical Co. Ltd. (1:14-cv-01117)?
Case posture: A patent infringement action filed by Cephalon, Inc. against Nang Kuang Pharmaceutical Co., Ltd. in the U.S. District Court for the District of New Jersey (2014). The case centers on Cephalon’s drug patents and alleged infringement by Nang Kuang’s ANDA-linked generic product.
Forum: U.S. District Court for the District of New Jersey, civil action number 1:14-cv-01117.
Litigation core: Cephalon asserted infringement of one or more Orange-Book-listed patents tied to its reference product, and Nang Kuang challenged those patents in the context of FDA ANDA marketing authorization.
What was Cephalon’s asserted patent estate?
The litigation’s legal and technical scope is anchored to Orange-Book patents for Cephalon’s relevant brand. Without the specific docket entries listing the asserted patents (and without the claim chart or the court’s claim-construction record), the asserted patent numbers, expiration dates, and claim coverage cannot be stated accurately from the case caption alone.
What relief did Cephalon seek?
Cephalon’s typical remedies in Hatch-Waxman patent suits are:
- Injunctions to bar generic launch until patent expiry or invalidation
- Damages for infringement for the pre-launch exposure tied to ANDA filing (and post-launch exposure if occurred)
- Attorney’s fees under the Patent Act in exceptional circumstances Exact requested relief can only be verified from the complaint and docket orders.
Which patents were asserted in 1:14-cv-01117 and how does that shape the infringement theory?
Answer: The specific asserted patents and their claim themes (composition, formulation, method-of-use, or manufacturing) are not recoverable from the case number and caption provided. Patent-level analysis requires the asserted claims list from the complaint or the court’s summary-judgment and infringement rulings.
Patent scope typically falls into these buckets
In Cephalon ANDA litigations, asserted patents often include:
- Drug substance or salt form coverage
- Formulation and dosage form patents (release profile, excipient systems, solid-state traits)
- Method-of-use claims (indication, dosing, or treatment regimen)
- Manufacturing or process claims
A correct analysis requires the actual asserted patent set for this docket.
What did Nang Kuang argue in its invalidity and non-infringement defenses?
Answer: The defenses Nang Kuang raised cannot be stated accurately without the docket’s substantive filings (answer, motions to dismiss, invalidity contentions, claim construction briefing, summary judgment submissions, and trial record if any).
Likely defense categories in Hatch-Waxman cases
These cases commonly include:
- Invalidity arguments: anticipation, obviousness, lack of enablement, indefiniteness, written description
- Non-infringement arguments: product differences versus claim limitations, including formulation and release/solid-state distinctions
- Section 112 and 103 challenges targeted to asserted claims
- Carve-outs tied to FDA label design or design-around
But the exact grounds and which patents they targeted must be verified from the case documents.
How did the court rule: claim construction, summary judgment, and final outcome?
Answer: The litigation outcome cannot be summarized accurately without the court’s orders and final judgment in 1:14-cv-01117.
What court actions matter for generic entry timing
In ANDA patent cases, the decision path typically includes:
- Markman/claim construction order narrowing claim terms
- Summary judgment on infringement and/or invalidity
- A final judgment on patent validity and infringement
- Entry of an injunction or a denial of injunctive relief
- Appellate activity if either party appealed
None of those determinations can be mapped reliably without the docket’s ruling content.
What Orange Book patents were at issue, and what was the exclusivity timeline?
Answer: Orange-Book listing data and exclusivity windows cannot be identified for this specific case without knowing the specific Cephalon reference product and the asserted patent numbers.
Why Orange Book data is decisive
Generic entry risk hinges on:
- Patent expiry dates of the asserted Orange-Book patents
- Any listed pediatric exclusivity adjustments
- Whether the patents are “fully litigated” or partially resolved
- Whether the case involves carve-outs or FDA label restrictions
Those facts must be tied to the asserted patents for this docket.
Was this a Paragraph IV or Paragraph III challenge under 21 U.S.C. §355(j)?
Answer: Paragraph certification type (IV vs III) and the ANDA filing details are not determinable from the case number alone. Correct litigation posture analysis requires the ANDA ANDA-related exhibit references in the complaint and FDA certification description.
Did the case end in a settlement, consent judgment, or an adjudicated judgment?
Answer: Settlement and its terms cannot be stated accurately without the docket showing a dismissal with prejudice, a settlement agreement filing, or a consent judgment order.
Settlement terms that drive market timing
When settlements occur in this fact pattern, they typically set:
- “Launch at risk” vs delayed launch schedules
- Date-certain entry permissions tied to patent expiry
- Damages caps or reverse payments in some cases
- License terms for the ANDA product
- Stipulated injunction duration
These are not verifiable here without the disposition order or settlement record.
What generic entry risks existed for Nang Kuang if Cephalon won?
Answer: The generic entry consequences cannot be quantified without:
- The asserted patent set and their expiry dates
- The court’s final findings on infringement and validity
- Whether a stay applied pending appeal
- Whether an injunction issued and for which claims/patents
Generic launch risk is driven by the number of remaining valid, infringed patents after each dispositive milestone.
How strong was Cephalon’s patent estate in this case?
Answer: Patent strength metrics (e.g., historical invalidity rates by patent family, claim breadth, and court treatment) cannot be computed accurately without identifying the asserted patents and the court’s reasoning.
What can be assessed once asserted patents are known
For each asserted patent, the analysis typically tracks:
- Claim scope relative to generic design-around features
- Prior art landscape and obviousness sensitivity
- Whether courts previously construed the same claim family terms
- Whether the patents are vulnerable to common Section 103 combinations
No court reasoning or asserted patent identifiers are available in the information provided.
How does this case compare with other Cephalon ANDA litigations?
Answer: A comparative analysis requires:
- Which Cephalon product (and patent family) is implicated
- The asserted patents and outcomes in 1:14-cv-01117
- The similarity of the generic product and the alleged infringement theory
Without the asserted patent/product identifiers, comparisons would be speculative.
What manufacturing or formulation design-arounds were likely at issue?
Answer: Likely design-around angles include excipient selection, release characteristics, solid-state form, particle size, and bioequivalence-related aspects. But this case’s actual infringement theory depends on claim elements and the accused product details, none of which are provided.
Key procedural timeline (what typically occurs in Hatch-Waxman cases, and what must be checked in this docket)
Answer: The specific dates for 1:14-cv-01117 (complaint filing, answer, claim construction deadlines, dispositive motions, trial date if any, and final judgment date) cannot be stated accurately without the docket event list.
Key Takeaways
- The docket number 1:14-cv-01117 identifies the Cephalon v. Nang Kuang case in the District of New Jersey, but a litigation summary with patent-level accuracy requires the asserted patent identifiers and the court’s orders, which are not present in the information provided.
- Without the complaint and the court’s disposition orders for this specific case, it is not possible to state:
- which patents were asserted,
- whether the case resolved via settlement or adjudication,
- what the court ruled on claim construction/infringement/invalidity,
- how those rulings affected the generic entry timeline.
FAQs
- What is the significance of the District of New Jersey forum in Cephalon Hatch-Waxman litigation?
- How do Paragraph IV vs Paragraph III certifications change infringement exposure in Cephalon cases?
- What court milestones typically determine whether a generic can launch “at risk”?
- How do formulation and solid-state claim elements affect generic non-infringement defenses?
- What docket events confirm whether Cephalon obtained an injunction or the case ended in a settlement?
References
- Cephalon, Inc. v. Nang Kuang Pharmaceutical Co. Ltd., 1:14-cv-01117 (D.N.J.).
More… ↓
